HP
TBPH icon

Hound Partners’s Theravance Biopharma TBPH Stock Holding History

Hound Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-49,830
Closed -$724K – 228
2021
Q2 		$724K Buy
+49,830
New +$936K 0.04% 196
2020
Q4 		– Sell
-57,200
Closed -$846K – 139
2020
Q3 		$846K Buy
+57,200
New +$1.07M 0.06% 93
2018
Q2 		– Sell
-42,082
Closed -$1.02M – 27
2018
Q1 		$1.02M Buy
+42,082
New +$1.16M 0.03% 22

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Hound Partners's TBPH Position: Q3 2021 in Review

Hound Partners sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 49,830 shares — an estimated $724K sold.

Hound Partners first reported a position in TBPH in Q1 2018 and held it in 3 quarters. The position peaked at $1.02M in Q1 2018. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • Hound Partners reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • Hound Partners sold 49,830 Theravance Biopharma shares in Q3 2021, an estimated $724K.
  • Hound Partners first reported a position in Theravance Biopharma in Q1 2018 and held it in 3 quarters.
  • Hound Partners's Theravance Biopharma position peaked at $1.02M in Q1 2018.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on Hound Partners's 13F filing for Q3 2021, filed 15 Nov 2021.